Diabetes mellitus as an immunosuppressive factor predisposing to mucormycosis: a case report
Main Article Content
Abstract
Objective: To report a case study of mucormycosis in a diabetic patient with late diagnosis and consequent unfavorable evolution. Case details: 48-year-old female patient with hypertension, diabetes, dyslipidemia and obesity. Initially, she presented with a non-specific headache and pain in the oral cavity. She was seen by a dentist who misdiagnosed her as having a dental infection and started her on amoxicillin with clavulanate. However, after a few days, her condition worsened and she sought medical attention. She already presented with an advanced condition and signs of systemic infection, and was then referred to an intensive care bed, where a fungal infection was hypothesized. Due to the severity and extent of the disease, it was decided not to perform surgery, but to continue with drug treatment. After a few days, the patient died. Final considerations: Mucormycosis is a serious and potentially fatal disease. It is an opportunistic infection, with the main group being people with decompensated diabetes mellitus. Diagnosis requires a high level of suspicion and immediate treatment, as a delay in diagnosis leads to an unfavorable outcome.
Article Details
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
References
2. BRUNET K e RAMMAERT B. Mucormycosis treatment: Recommendations, latest advances, and perspectives. Journal de Mucologie Medicale, 2020; 30 (3): 101007.
3. CHIKLEY A, et al. Mucormycosis of the Central Nervous System. Journal of Fungi, 2019; 5(3): 59.
4. CORNELLY OA, et al. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. The Lancet.Infectious diseases, 2019; 19 (12): 405-421.
5. DARWISH RM, et al. Mucormycosis: The hidden and forgotten disease. Journal of applied microbiology, 2022; 132(6): 4042-4057.
6. FATHIMA AS, et al. Mucormycosis: A triple burden in patients with diabetes during COVID-19 Pandemic. Health Sciences Review. Health Sci Rev (Oxf), 2021; 1(3): 100005.
7. FERNADES KT e BASTOS ASM. Mucormicose em pacientes portadores de diabetes mellitus: uma revisão de literatura. Revista Ibero-Americana de Humanidades, Ciências e Educação, 2022; 8 (8): 398-404..
8. GUAN WJ, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. The Journal of Emergency Medicine, 2020; 58(4): 711-712.
9. HASSAN MIA e VOIGT K. Pathogenicity patterns of mucormycosis: epidemiology, interaction with immune cells and virulence factors. Medical Mycology, 2019; 57 (2): 245–256.
10. HERRERA EM, et al. Mucormicose rinocerebral em alta? O impacto da epidemia mundial de diabetes. Anais Brasileiros de Dermatologia, 2021; 96 (2): 196 -199.
11. VASUDEVAN B, et al. Mucormycosis: the scathing invader. Indian Journal of Dermatology, 2021; 66 (4): 393-400.
12. MINISTÉRIO DA SAÚDE. Mucormicose (fungo negro). 2021. Disponível em: https://www.gov.br/saude/pt-br/assuntos/saude-de-a-a-z/m/mucormicose. Acessado em: 01 de dezembro de 2023.
13. PAI V, et al. Rhino-orbito-cerebral Mucormycosis: Pictorial Review. Insights into Imaging, 2021; 12 (1): 167.
14. REID G, et al. Mucormycosis. Seminars in respirator and critical care medicine, 2020; 41 (1): 99-114.
15. SKIADA A, et al. Epidemiology and diagnosis of mucormycosis: an update. Journal of fungi, 2020; 6 (4): 265.
16. SMITH C e LEE SC. Current treatments against mucormycosis and future directions. PLoS Pathogens, 2022; 18 (10): 1010858.
17. STEINBRINK JM e MICELI MH. Mucormycosis. Infectious Disease Clinics of North America, 2021; 35 (2): 435–452.